Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Abivax To Launch ‘Triple-Action’ COVID-19 Therapy Trial

Data Show Anti-inflammatory ABX464 inhibits SARS-CoV-2 Viral Replication In Lung

Executive Summary

Abivax will test its anti-inflammatory ABX464 in early COVID-19 patients after the small molecule showed it could reduce SARS-CoV-2 viral replication in human lung tissue in addition to its anti-inflammatory and tissue-healing effects.    

You may also be interested in...



AbiVax Poised For 'Transformational' Q2

Q2 promises to be ‘transformational’ for AbiVax, propelled by key readouts for investigational anti-inflammatory, ABX464, and cancer agent, ABX196, but more funds will be needed by year end.

Interview: AbiVax Equipped To Enter Anti-Inflammatory Market

The French biotech's CEO tells Scrip the firm now has the time and resources to sign up a big pharma partner for its ulcerative colitis, RA and Crohn’s candidate.

Anjarium To Pioneer Next-Generation Non-Viral Gene Therapies

Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.   

Topics

Related Companies

UsernamePublicRestriction

Register

SC142216

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel